teicoplanin Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Teicoplanin is an semisynthetic glycopeptide antibiotic with a spectrum of activity similar to vancomycin. Its mechanism of action is to inhibit bacterial cell wall peptidoglycan synthesis. It is used in the prophylaxis and treatment of serious infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus and Enterococcus faecalis.   Wikipedia

Chemistry

  • SMILES: N[C@H]1C(=O)N[C@@H]2Cc3ccc(Oc4cc5cc(Oc6ccc(cc6Cl)[C@@H](O)[C@@H]7NC(=O)[C@H](NC(=O)[C@@H]5NC(=O)[C@@H](NC2=O)c8cc(O)cc(Oc9cc1ccc9O)c8)c%10ccc(O)c(c%10)c%11c(O)cc(O)cc%11[C@H](NC7=O)C(=O)O)c4O)c(Cl)c3
  • InChIKey: DKVBOUDTNWVDEP-NJCHZNEYSA-N
  • Mol. Mass: 1198.94
  • ALogP: Missing data
  • ChEMBL Molecules:
    teicoplanin aglycon  
    teicoplanin  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

aglucoteicoplanin | antibiotic 8327a | antibiotic a 41030b | antibiotic mdl 507 | mdl-507 | targocid | targosid | teic | teichomycin | teichomycin a2 factor 2 | teicoplanin | teicoplanin aglycon | teicoplanin aglycone

Organizations (24)

Research & Development (24)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (23)

Approved Indications (1)


 

Sepsis

Experimental Indications - Clinical Trial Phases 1-4 (22)


 

Amputation, Surgical (Phase 4)

Arthroplasty (Phase 4)

Bacteremia (Phase 4)

Bacterial Infections ()

Catheter-Related Infections (Phase 4)

Clostridium Infections (Phase 4)

Cystic Fibrosis (Phase 1)

Febrile Neutropenia (Phase 4)

Infections (Phase 4)

Liver Cirrhosis, Biliary (Phase 4)

Lumbar Vertebrae (Phase 3)

Neurosurgery (Phase 1)

Osteomyelitis (Phase 2)

Patient Compliance (Phase 4)

Pharmacology (Phase 4)

Scoliosis (Phase 3)

Skin Diseases, Infectious (Phase 3)

Soft Tissue Infections (Phase 3)

Spinal Stenosis (Phase 3)

Spondylolisthesis (Phase 3)

Staphylococcal Infections (Phase 4)

Wound Infection (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 17
  • # of Trial Organizations: 24

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue